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Abstract 
 
Priming and activation of CD4+ T helper (TH) cells against tumor associated antigens can be 
achieved after their recognition on antigen presenting cells (APCs) only within the context of 
MHC class II (MHC-II) molecules. We previously reported successful triggering of TH-specific 
long lasting anti-tumor immune response in H-2d haplotype BALB/c mice using tumor cells 
genetically modified to express endogenous MHC-II genes (I-A and I-E) after transfection with 
CIITA (MHC-II transactivator). Now, we aim to investigate the pertinence of this approach in 
H-2b haplotype C57BL/6 mice that only express I-A molecules due to a defect in their I-Eα gene.  
MC38 colon carcinoma cells of the H-2b haplotype were stably transfected with CIITA. Selected 
MHC-II positive clones were injected into C57BL/6 mice. Complete rejection or significant 
growth retardation as compared to MHC-II negative parental tumor was obtained. Subsequent 
challenge of the protected mice with parental tumor proved that the CIITA-transfected tumor 
engendered efficient anti-tumor vaccination. Then, adoptive cell transfer from the vaccinated 
mice to naïve recipients demonstrated that CD4+ TH cells orchestrate the anti-tumor protection. 
Finally, the use of CD11c.DTR transgenic mice in which conditional depletion of dendritic cells 
(DCs) can be performed, and the use of Liposomal Clodronate as a depletion agent for 
macrophages, proved that CIITA-driven MHC-II positive tumor cells act as surrogate APCs for 
priming and activating CD4+ TH cells, without the need of either DCs or macrophages. 
These results demonstrate the validity of CIITA-driven MHC-II+ tumor cells as anti-tumor 
vaccination tool in mouse models of different haplotypes. Moreover, they prove that expression 
of a single MHC-II restriction element in tumor cells is sufficient to trigger anti-tumor CD4+ TH 
cells and, more importantly, demonstrate for the first time that CIITA-driven MHC-II expressing 
tumor cells can act as professional APCs in vivo to prime naïve tumor-specific CD4+ TH cells.  
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Introduction 
 
The rise of the global cancer burden to 4.1 million new cases per year, 8.2 million cancer-caused 
deaths in 2012 and the expectations that the number of new cases will increase by about 70% 
over the next two decades strongly urge additional basic and applied research efforts to 
counteract this plague [1]. Nowadays, a significant part of cancer research is directed towards 
immunotherapy due to the evident existence of an immune response against neoplastic cells and 
the fact that cancer does not take off in an organism unless cancer cells display reduced 
immunogenicity or exhibit an increased inhibiting capacity against protective anti-tumor immune 
responses [2], [3]. 
 
It is widely accepted that tumor-specific CD4+ TH cells play a pivotal role in anti-cancer 
immunity, mainly because they provide help in proliferation, differentiation and maintenance of 
CD8+ T cells that are believed to be the major anti-tumor effector cells. In fact, priming of CD8+ 
T cells in the absence of CD4+ TH cells lead to their “helpless” activation in terms of clonal 
expansion and acquisition of cytolytic function. Nevertheless, most of the strategies of active and 
passive cancer immunotherapies have focused on stimulating primarily cytolytic CD8+ T cells 
(CTL) with tumor-associated antigens (TAA) presented by MHC-I molecules, which are 
expressed on the surface of the majority of tumor cells and thus are more easily identifiable with 
respect to MHC-II restricted TAA by biochemical tools [4], [5], [6], [7], [8]. 
 
In a new approach aiming instead at the optimal stimulation of tumor-specific TH cells, our group 
already launched and published many studies based on animal vaccination using tumor cells 
transduced with the AIR-1-encoded CIITA, the MHC-II transactivator [9]. The idea underlying 
this approach was to make the tumor cells expressing MHC-II molecules, hoping that they would 
present MHC-II-restricted TAA directly to the TH cells and thus act as surrogate APCs of their 
own tumor antigens in vivo. Using this approach, we proved that a complete tumor rejection and 
specific antitumor memory against tumors of different histotypes can be achieved  in the Balb/c 
mouse model of the H-2d haplotype [10], [11], [12]. 
   
In the present work we assessed the pertinence of this vaccination approach in tumor models of 
the C57BL/6 mouse expressing the H-2b haplotype. C57BL/6 mice hold a resilient challenge 
because one of the two possible MHC class II molecules, I-A and I-E, namely the I-E molecule 
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cannot be expressed because of a mutation in its I-Ea gene. Thus only the I-A molecule is 
expressed on the surface of the H-2b cells [13], [14]. 
Moreover, a transgenic C57BL/6 mouse model is available in which it is possible to transiently 
deplete DCs believed to be the crucial APCs for priming CD4+ TH cells [15] offering the 
possibility to unambiguously assess whether CIITA-driven MHC-II-expressing tumor cells could 
still trigger a protective anti-tumor response in vivo in absence of the major source of professional 
APCs. 
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Part I.  
Chapter 1: Overview on The Immune System 
 
The immune system is an interactive network of lymphoid organs, cells, humoral factors, and 
cytokines. The essential function of this system is to protect the organism against all kinds of 
disease-causing microorganisms or pathogens like viruses, bacteria, fungi, parasites. The reaction 
of the immune system against pathogens is known as the immune response and depending on its 
speed and specificity can be divided into two arms: The innate and adaptive immune responses 
[16], [17]. 
	
1.  The innate immune response 
  
Innate immunity (also called natural or native immunity) provides the early line of defense against 
pathogens. It is a highly conserved form of response and is seen in even the simplest animals 
confirming its importance in survival. It consists of cellular and biochemical defense mechanisms 
that are in place even before infection and react rapidly, in terms of hours, to the infections. These 
mechanisms are not specific for each pathogen and respond in essentially the same way to 
repeated exposures of microbes without distinguishing the differences between them. The 
principal components of innate immunity are (1) physical and chemical barriers, such as epithelia 
and antimicrobial chemicals produced at epithelial surfaces; (2) phagocytic cells (neutrophils, 
macrophages), dendritic cells, and natural killer cells and (3) blood proteins, including members 
of the complement system and other mediators of inflammation [17], [18]. 
 
2.  The adaptive immune response 
 
Adaptive immunity is triggered when an infection overwhelms the innate defense mechanisms 
and generates a threshold level of antigen. It is highly specific to a particular pathogen and can 
also provide long-lasting protection called immunological memory. The adaptive immune 
response is initiated in the peripheral lymphoid organs like lymph nodes, spleen, and the mucosa-
associated lymphoid tissues such as the Peyer's patches of the gut. The main components of the 
adaptive immune response are the two primary types of lymphocytes, B and T. They both 
originate from stem cells in the bone marrow then some of them migrate to the thymus, where 
they mature into T cells while others remain in the bone marrow, where they develop into B cells. 
10 
	
Two distinct sets of highly variable receptor molecules serve as antigen-specific receptors on B 
cells (BCR) and T cells (TCR), and the adaptive immune response can be divided into two types 
depending on which one of these two lymphocyte subpopulations, B or T, will be responsible of 
the response [16]. 
 
2.1- Humoral immune response  
 
Through their BCR, the B cells bind native proteins, glycoproteins, and polysaccharides, as well 
as whole virus particles and bacterial cells, by recognizing epitopes on their surfaces. Then the B-
cell antigen receptor delivers the bound antigen to intracellular sites, where it can be degraded to 
give peptides that are returned to the B-cell surface bound to major histocompatibility complexes 
class II (MHC-II) molecules. These peptide:MHC-II complexes, are recognized by antigen-
specific TH cells that have already differentiated in response to the same pathogen. The B cell-T 
cell interaction is strengthen by the binding of co-stimulatory molecules, CD40-CD40 ligand 
(CD40L) respectively, that start to be expressed on the surface of these cells after the antigen 
recognition. As a result of this interaction, the effector T cells secrete cytokines that cause the B 
cell to proliferate and its progeny to differentiate into antibody-secreting cells or plasma cells and 
into memory B cells (Scheme 1, top first and second panels) [16].  
Antibodies, that are the characteristic targeted effectors of the humoral immune response, protect 
the host from infection in three main ways. First, they can inhibit the toxic effects of pathogens 
by binding to them, which is termed neutralization (Scheme 1, bottom left panel). Second, by 
coating the pathogens they can enable accessory cells that recognize the constant fragments (Fc) 
portions of antibodies to ingest and kill the pathogen, a process called opsonization (Scheme 1, 
bottom center panel). Third, antibodies can trigger the activation of the complement system. 
Complement proteins strongly enhance opsonization, and can directly kill certain bacterial cells 
(Scheme 1, bottom right panel) [16] . 
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2.2- Cellular immune response 
 
The cellular immune response is also called T cell-mediated immune response since the T 
lymphocytes are its main effectors. Unlike B cells, T cells only recognize antigens that are 
displayed on cells surface. In order to trigger a T cell-mediated immune response, a naïve T cell 
must meet its specific antigen, presented as a peptide within the context of MHC molecules on 
the surface of an APC and thus be induced to proliferate and differentiate into antigen-specific 
effector cells. The peptides presented by MHC molecules can be derived for example from 
pathogens that replicate within cells, such as viruses or intracellular bacteria, or from pathogens 
or their products that cells have taken up from the extracellular fluid.  Unstimulated naïve T cells 
fall into two large classes, one that carries the co-receptor CD8 on its surface and the other the 
co-receptor CD4. Upon antigen recognition, naïve T cells differentiate into several functional 
classes of effector T cells that are specialized for different activities. Naïve CD8+ T cells 
Scheme 1 The main steps of the humoral 
immune response (from Janeway 
Immunobiology, 8th edition) 
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recognize pathogen peptides presented by MHC-I molecules on the surface of APCs and 
differentiate into cytotoxic effector T cells that recognize and kill all infected cells. CD4+ T cells 
have a more flexible repertoire of effector activities. After recognition of pathogen peptides 
presented by MHC-II molecules on the surface of APCs, naïve CD4+ T cells can differentiate in 
distinct pathways to generate different effector subsets. The main subsets currently distinguished 
are: TH1, TH2, TH17 and several regulatory T cell subsets with inhibitory activity that limit the 
extent of immune activation [16], [18]. 
 
2.2-1. CD8+ T cells 
 
CD8+ T cells are very important for immune defense not only against intracellular pathogens, 
including viruses and bacteria, but also against tumors. The infected cells display fragments of 
pathogen-derived proteins as peptide-MHC class I complexes on their surface that are recognized 
by the activated CD8+ T cells or CTLs. When a CD8+ T cell recognizes its antigen and becomes 
activated, it has two major mechanisms to kill infected or malignant cells. The first major 
function is the production and release of cytotoxic granules that contain two families of proteins, 
perforin, and granzymes. Perforin forms pores in the membrane of the target cell that allow the 
granzymes to enter the infected cell, cleaving and activating a family of proteins (caspases) that 
trigger cell death by apoptosis (Scheme 2, A). 
The second major way for CTLs to destroy infected cells is via Fas/FasL interactions. Activated 
CD8+ T cells express FasL on their cell surface, which binds to its receptor, Fas, on the surface 
of the target cell. This binding causes the Fas molecules on the surface of the target cell to 
trimerise, which pulls together signaling molecules resulting in the activation of the caspase 
cascade and consequent apoptosis of the target cell (Scheme 2, B) [16], [17], [18].  
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The priming and activation of naïve CD8+ T cells happens usually after the recognition of a 
pathogenic peptide in context of MHC-I on the surface of APCs (Scheme 3). In most instances, 
CD8+ T cell activation requires crucial help provided by CD4+ effector T cells. Help is provided 
mainly via the production of a specific class of hormones, designated cytokines needed to amplify 
the stimulation and activate the proliferation of both CD8+ and CD4+ T cells. In this context 
CD8, CD4 and dendritic cells further interact via co-stimulatory molecules within the same 
microenvironment. Upon interaction CD4+ T cells produce several cytokines among which the 
cytokine Interleukin-2 (IL-2) is the major driver of T cell proliferation and maturation (Scheme 
3) [18].  
  
 
 
 
 
 
 
Scheme 2 Mechanism of CTL mediated toxicity (from Cellular and Molecular Immunology, 8th edition) 
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2.2-2. CD4+ T cells 
 
The priming of naïve CD4+ T cells takes place also in the peripheral lymph nodes were the APCs 
migrate after catching and processing the pathogen’s antigen from the periphery. The priming 
can be triggered in only one way that include 3 steps or signals: Signal 1 comprises the antigen-
specific signal derived from the interaction of a specific peptide-MHC-II complex with the TCR 
and its co-receptor, the CD4 molecule. Then the survival and expansion of the naïve cell are 
promoted after the delivery of signal 2 by the co-stimulatory molecules. The best known co-
stimulatory molecule is CD28, receptor of the B7 molecules that are expressed on the APCs 
surface. The final signal 3 is triggered by the different molecules and cytokines secreted by the 
APCs or by T cells. Depending upon the nature of these soluble molecules, naïve CD4+ T cells 
mature in distinct subsets of effector T cells (Scheme 4). For example, the differentiation into 
TH1 is triggered by the secretion of IL-12 by the APC and IFN-γ by the T cell, whereas the 
differentiation into TH2 is triggered mainly by IL-4 [16]. 
Scheme 3 Amplification of CD8+ T cell 
response by CD4+ T cell (from Janeway 
Immunobiology, 8th edition) 
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Scheme 4 Priming of naive CD4+ T cells by 3 signals provided by APCs (from Janeway Immunobiology, 8th edition)  
	
The distinct polarization of CD4+ T cells, THl, TH2, TH17, and the regulatory T cells (Treg) is 
largely defined on the basis of the different combinations of cytokines they secrete. 
Briefly, TH1 cells produce different types of cytokines, essentially IFN-γ and IL-2, that activate 
phagocytosis and foster the development of cytotoxic lymphocytes that are the main effectors of 
cell-mediated immune response against viruses and tumor cells. In fact, IFN-γ also upregulates 
the expression of MHC-I and MHC-II molecules on a variety of cells especially the ones that are 
infected by or have ingested pathogens, thereby stimulating antigen presentation to T cell 
(Scheme 5, 1st panel). TH2 cells are specialized for promoting immune responses to parasites 
and also promote allergic responses. They provide help in B cell activation and secrete the B cell 
growth factors IL-4, IL-5, IL-9, and IL-13. The principal membrane-bound effector molecule 
expressed by TH2 cells is CD40L, which binds to CD40 on B cells and induces B-cell 
proliferation and isotype switching (Scheme 5, second panel). TH17 cells produce members of 
the IL-17 family and IL-6, and promote acute inflammation by helping the recruitment of 
neutrophils to sites of infection (Scheme 5, 3rd panel). Treg cells, of which there are several types, 
produce inhibitory cytokines such as IL-10 and TGFβ and exert inhibitory actions through 
different mechanisms (Scheme 5, 4th panel) [16]. 
16 
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Scheme 5 The different subsets of CD4+ effector T cells and the molecules that they secrete or express (from 
Janeway Immunobiology, 8th edition)   
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Part I.  
Chapter 2: Major Histocompatibility System and Antigen 
Presentation 
 
As it was already mentioned, the T cells can only recognize antigens in the context of MHC class 
I or class II molecules on the surface of the cells. These proteins were first discovered as 
histocompatibility antigens considering their prominent role in the acceptance or rejection of a 
grafts from an unrelated donor. MHC class I and class II molecules are encoded by the MHC 
system that accommodates more than 100 distinct genes. It is designated as Human Leukocyte 
Antigen or HLA in human, and H-2 in mice. The MHC system has three major characteristics 
that contribute to its large diversity and complexity within the species: (1) it is extremely 
polymorphic; (2) is polygenic; (3) both haplotypes are co-dominantly expressed.  
The genetic organization is similar in both human and mouse (Scheme 6). In human, there are 
three class I MHC genes called HLA-A, HLA-B, and HLA-C encoding the three types of MHC-
I molecules and three subsets of MHC class II genes encoding the three distinct class II molecules 
HLA-DP, HLA-DQ, and HLA-DR. Similarly, in mice, three genes H-2K, H-2D, and H-2L 
encode class I MHC proteins K, D and L that are homologous to human HLA class I genes. On 
the other hand, mice have only two expressible MHC-II loci that encodes the I-A and I-E MHC-
II proteins (Scheme 6) [16], [18], [19].  
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Scheme 6 Gene structure of human and mouse MHC (from Cellular and Molecular Immunology, 8th edition) 
 
1. MHC-I molecules 
 
MHC-I molecules are composed of two non-covalently linked polypeptide chains, an MHC-
encoded α heavy chain of 44 to 47 KDa and a non-MHC-encoded β2-microglobulin of 12 KDa 
(Scheme 7). The heavy chain consists of three extracellular domains α1, α2, and α3 which are 
about 90 amino acids long each. The antigen-binding groove or cleft of MHC-I is confined to the 
α1 and α2 domains including most of the polymorphic aminoacid residues. The α3 chain is 
conserved among all class I molecules and folds into an immunoglobulin (Ig)-like domain that 
contains the binding sites for CD8 molecule expressed on T cells and for the β2m. The β2m is 
crucial for MHC-I expression on the cell surface. Mice having their β2m gene mutated do not 
express MHC-I molecules and are severely defective in antigen presentation to T cells [18], [19].  
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Scheme 7 The structure of MHC class I molecule (from Abbas, Cellular and Molecular Immunology,8th edition) 
  
MHC-I molecules are expressed on all nucleated cells and are responsible for presenting peptides 
from processed proteins of cytosolic and nuclear origin at the surface of the cell (Scheme 8). 
These proteins are tagged for degradation in the proteasomes and should translocate into the 
endoplasmic reticulum (ER) through a molecular heterodimer designated TAP (transporter 
associated with antigen presentation) in order to be scrutinized for binding to MHC-I molecules. 
In the ER, MHC-I molecules are bound to chaperone-like proteins such as calreticulin or Tapasin 
that are essential for the stability of the molecule. Once they interact with the complementary 
peptide, usually 8-9 aminoacid long, MHC class I molecules are exported outside the ER, 
undergo post-synthetic modifications, such as glycosylation, in the Golgi and finally migrate to 
the cell surface [20], [21].  
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Scheme 8 Pathways of antigen processing and presentation (from Abbas, Cellular and Molecular Immunology, 8th 
edition) 
 
2. MHC-II molecules 
 
 MHC-II molecules are composed of two non-covalently linked polypeptide chains an α chain of 
34 to 36 KDa and a β chain of 26 to 32 KDa, that, unlike MHC-I molecules, are both MHC 
encoded. The polymorphic residues of both chains reside in the α1 and β1 domains. These 
domains form the peptide binding cleft that is open at both ends and for this reason it may 
accommodate longer peptides, up to 30 amino acids, with respect to those bound to MHC class 
I molecules. The α2 and β2 segments of class II molecules, similar to class I α3 and β2-
microglobulin, are folded into Ig domains, are non-polymorphic and contain the binding site for 
the CD4 molecule (Scheme 9) [18], [19].  
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Scheme 9 Structure of a class II MHC molecule (from Cellular and Molecular Immunology, 8th edition) 
 
Unlike MHC-I molecules, MHC-II have a restricted cell type expression. They are expressed 
mainly on dendritic cells, macrophages, and B cells. Under certain functional stimuli, as for 
example by IFN-γ, they may be expressed in other cell types, including epithelial and endothelial 
cells. They are in charge of presenting exogenous proteins to CD4+ T cells (Scheme 8). The 
initial step in the exogenous antigen presentation pathway of MHC-II is the internalization of the 
exogenous proteins in endosomal vesicles where they are degraded. Meanwhile, in the 
endoplasmic reticulum, MHC-II molecules are assembled from an α and a β chain and associate 
with the invariant chain to prevent the binding of proteins present in the endoplasmic reticulum 
to the peptide-binding cleft. The alpha-beta-invariant chain complexes are then routed to the 
endosome-lysosome compartment where they find the digested proteins derived from exogenous 
sources. Inside the fused vesicle, the same proteolytic enzymes that degraded the internalized 
protein digest the invariant chain leaving a 24-amino acid remnant referred to as the class II-
associated invariant chain peptide (CLIP). The CLIP is then removed allowing the binding of the 
30-amino acid long peptide in the MHC-II peptide-binding cleft. The MHC-II-peptide complex 
is finally transported to the cell surface where the exposed peptide can undergo  CD4+ T cell 
scrutiny [18], [21].  
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2.1- MHC-II molecules and CIITA 
 
The expression of MHC-II gene expression is tightly regulated at the transcriptional level. The 
major controller of this expression is a master regulator, designated class II transactivator 
(CIITA) [22], [23]. The identification and characterization of CIITA was accomplished after the 
generation of a somatic cell mutation that resulted in a MHC-II negative gene expression in RJ 
2.2.5 human B cells [24]. The mutant phenotype was complemented by somatic cell 
hybridization with murine MHC-II positive cells revealing the presence of a dominant locus 
encoding the trans-acting activator and acting across species barriers. This locus was mapped to 
mouse chromosome 16 and designated Air-1 [25], [26], [27]. Subsequently, the product of the 
Air-1 human equivalent gene was cloned by a gene complementation approach and was referred 
to as CIITA [28].   
 
CIITA transcription itself is controlled by a large regulatory region that contains four distinct 
promoters identified as pI, pII, pIII and pIV [29]. Promoters pI, pIII and pIV of CIITA gene are 
highly conserved in mouse and human; however, an equivalent promoter for pII has not been 
identified in mice and its function in human is not acknowledged yet. Each promoter controls the 
expression of CIITA in a cell specific manner. Early studies indicated that pI is responsible for 
CIITA transcription in DCs, pIII was specifically active in B cells, and pIV is IFN-γ induced 
[29], [30]. Several subsequent studies revealed that pI promoter is a myeloid cell specific 
promoter that is responsible of the expression of CIITA in conventional DCs and IFN-γ activated 
macrophages. The promoter pIII is active in lymphoid cells, B and T cells in addition to 
plasmacytoid DCs. The promoter pIV is important in CIITA expression in thymic epithelial cells 
[31].   
 
Once CIITA is expressed, it controls the transcription of MHC II genes by binding to DNA-
binding proteins, which themselves bind to DNA sequences 150 to 300 base pairs upstream the 
transcription initiation site (Scheme 10). This regulatory module designated SXY consists of four 
DNA sequences, S, X1, X2 and Y boxes. Moreover, the SXY is also found upstream accessory 
genes needed for MHC-II function, such as the invariant chain. The RFX (regulatory factor X 
consisting of RFX5, RFXANK-RFXB and RFXAP) protein complex binds to the X1 box of the 
SXY; CREB (cyclic AMP response element binding protein) interacts with the X2 box and NF-
Y (nuclear factor Y consisting of NF-YA, NF-YB and NF-YC) binds to the Y box. All these 
DNA binding proteins interact with CIITA to regulate MHC-II transcription. CIITA is also 
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capable of recruiting histone methylases and histone acetyl-transferases (HATs) to enhance gene 
activation [31].  
 
	
Scheme 10 Mechanism of Action of CIITA (from Hoffman et al, 2006 Nature Reviews) 
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Part I. 
Chapter 3: Cancer Immunosurveillance, Escape and 
Immunotherapy  
 
Cancer has thrived to be one of the most hazardous health problems worldwide leading to high 
morbidity and mortality rates in adults and in children as well. The onset, expansion, persistence 
and spreading of tumors are under the control of a complex series of events that encompass both 
intrinsic modifications of cancer cells (such as genetic mutations in proto-oncogenes and in tumor 
suppressor genes, and alteration of the apoptotic process), which cumulatively impact on the 
homeostasis of the cell cycle, as well as extrinsic mechanisms related to the capacity of the host to 
counteract tumor growth.  The concept that the immune system can protect the host by detecting 
and eliminating cancer cells has been widely debated over the years. Some discoveries show that 
indeed the immune system is important for destroying tumor cells; on the other hand, other 
evidences indicate that the immune system can also indulge tumor growth by favoring the escape 
of the most aggressive tumor cells that are capable of developing escape mechanisms from the 
immune response. These findings have led to the development of a refinement hypothesis of 
immunosurveillance termed cancer immunoediting hypothesis, which has been used to describe 
the host protective role and the tumor escape [18], [32], [33]. 
Immunoediting comprises three different phases: elimination, equilibrium and escape (Scheme 
11). Elimination represents the host defense against tumor cells or immunosurveillance. 
Equilibrium embodies the period after the immune system failed to eliminate all tumor cells and 
escape refers to the growth of tumor cells that have successfully surpassed any immunological 
surveillance [32]. 
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Scheme 11 The three Es of cancer immunoediting (from Gavin P. Dunn et al. 2002, Nature Immunology) 
	
It is recognized that the mechanisms tumor cells use to escape the immune system lay in two basic 
categories: tumor intrinsic mechanisms associated with tumor cells and tumor-associated antigens, 
and tumor extrinsic mechanisms associated with the host immune system. The first group includes 
the lack of expression of MHC II molecules and costimulatory molecules, down regulation or loss 
of expression of MHC I molecules, downregulation of expression of genes associated with antigen 
processing and presentation such as TAP or β2m, low level of expression of tumor associated 
antigens at early phases of tumor growth, loss of antigenic peptides, physical barrier preventing 
effector cells accessing tumors, and loss of response to IFNs. The second group includes 
mechanisms of tolerance of T cells to tumor-specific antigens, suppression of T cells caused by 
tumor derived factors, defects in antigen presentation by professional APCs, and impaired APCs 
maturation [32].  
 
It is therefore apparent that potential immunological approaches to counteract tumor growth and 
spreading have to be focused at eliminating and/or bypassing the above escape mechanisms. Many 
therapeutic strategies have been used in the past, such as peptide vaccination aimed at eliciting 
tumor specific CTLs, cytokine injection to rescue potential effector cells from latency and low 
replication, injection of DCs pulsed with class I restricted peptides.  However, none of these 
elicited the expected or hoped optimal recovery mostly because optimal triggering of CD4 TH 
cells was not targeted. As mentioned earlier in the introduction TH cells are crucial in all cellular 
and humoral immune responses. For instance, CD8+ T cell cannot be efficiently activated and no 
memory cell will be generated without a further help from CD4+ TH cell [4], [6], [7], [8]. 
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Part II. 
 
II.1- Our Approach and Previous Results 
 
The approach of our laboratory is specifically directed to the optimal stimulation of tumor-
specific CD4+ TH cells for their key role in leading a strong, long lasting adaptive immune 
response. In order to increase the triggering of tumor-specific TH cells we used a strategy that 
consists in a genetic modification of the tumor cells by stably transfecting them with the cDNA 
of CIITA. This modification induces the optimal and “physiological” expression of MHC-II 
molecules on tumor cell surface. The believe was that if MHC-II molecules can be expressed in 
tumor cells, these cells may function as surrogate APCs for their own TAA and directly prime 
and activate CD4+ TH cells and consequently enhance CTLs activation. The approach is 
summarized in the following scheme 12.	 Different tumor cell lines originated from distinct 
tissues and sharing the same H-2d genetic background were successfully used in this approach. 
Indeed, following this concept, it was demonstrated that CIITA-induced MHC class II-expressing 
tumor cells can be recognized in vivo and elicit both tumor-specific CTLs and, more importantly, 
tumor specific CD4+ TH cells [10], [11], [12].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 12 Tumor Cell as Antigen Presenting Cells (from ACCOLLA and TOSI 2013, Journal of Neuroimmune 
Pharmacology) 
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II.2- Aim of The Project  
 
1. The prominent goal of my thesis project was to verify whether mice with a different genetic 
background such as the one represented by C57BL/6 (H-2b haplotype) can mount an adoptive 
immune response against CIITA-driven MHC-II positive tumor cells, similar to the one observed 
in Balb/c (H-2d haplotype) mice. If this takes place then our approach could be generalized not 
only to tumor cells of distinct histotypes, as previously shown [12], but also to distinct MHC 
haplotypes/genotypes, and give further support to extend our approach to human clinical setting. 
 
2. The choice of the C57BL/6 mouse model was also further motivated by the fact that these 
mice have a defective I-Eα gene and therefore they can express only MHC class II I-A 
heterodimers and not I-E heterodimers [13].  Their repertoire of MHC class II-restricted antigens 
is thus qualitatively and quantitatively distinct from the one expressed by the Balb/c mice and 
this may represent an additional immunological diversity between the two mice strains to 
investigate the adaptive response against the tumor. 
 
3. Moreover, and importantly, in the C57BL/6 mouse model, we could take advantage of the 
CD11c.DTR transgenic mouse system (H-2b haplotype), a mouse strain in which a conditional 
deletion of DCs can be induced. We could then verify whether CIITA-driven MHC-II positive 
tumor cells can be still recognized and rejected in absence of DCs. If this were the case, our 
hypothesis that CIITA-transfected MHC-II positive tumor cells act in vivo as APCs for TH cells 
priming could be unambiguously demonstrated. 
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Part III.   
Chapter 1: Materials and Methods 
 
1. Transfection and phenotypic analysis of tumor models 
MC38 colon carcinoma, a cell line of C57BL/6 H-2b haplotype from a female mouse, was 
cultured in Dulbecco's Modified Eagle Medium, DMEM, with 4.5 g/l Glucose, L-Glutamine and 
supplemented with 10% of heat-inactivated fetal calf serum (FCS) (Lonza BioWhittakerTM, 
Catalog number: BE12-604F). 
The full-length human CIITA cDNA was already inserted into the Xho-I site of the pLXIN 
retroviral vector (Clontech, Catalog number 63150). DNA transfections were performed using 
FuGENETM HD Transfection Reagent (PromegaTM, Catalog number: E2312), following the 
manufacturer’s instructions with a 1:3 ratio of µg DNA: µg of Transfection reagent respectively. 
MHC-II positive transfectants were sorted by magnetic beads and stable clones were selected by 
limited dilution cloning. The tumor cell line was also transfected with pLXIN empty vector as a 
control. 
The expression of different immune markers was assessed on the surface of the transfected and 
parental cell lines by immunofluorescence and flow cytometry (BD FACSAriaTM II Cell Sorter, 
BD Biosciences, San Jose, CA 95131 USA) using the following antibodies: M1/42 anti-H2 class 
I (Biolegend®, Catalog number: 125508), M5/114.15.2 anti-IA/IE (Biolegend®, Catalog 
number:107626), 16-10A1 anti-CD80 (Biolegend®, Catalog number:104705), GL1 anti-CD86 
(Becton Dickinson, Catalog number:558703) and M1/70 anti CD11b (Affymetrix eBioscience, 
Catalog number:17-0112-82). 
 
2. In vitro proliferation rate assay 
MC38-CIITA and MC38 cells were plated in triplicates in 24 wells plate, 5x104 cells per well. 
Proliferation rate and cells viability were assessed using trypan blue and Neubauer Chamber 
every 24 hours for 3 days. 
 
3. Vaccination and challenge 
7-9 weeks old C57BL/6 female mice (Charles River Laboratories Italia SRL, Calco, Italy) were 
subcutaneously (s.c.) injected with 5x104 of MC38 parental or CIITA-transfected tumor cells, 
resuspended in 100 µl of RPMI (Lonza BioWhittakerTM, Catalog number: BE12-702F) without 
FCS. The expression of CIITA-driven MHC-II was confirmed the day of the injection by 
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immunofluorescence and flow cytometry as described above. Tumor growth along with the 
overall health condition of the mice were checked at least twice a week. The tumors were 
measured weekly using a caliper and registered in mm2. 
The mice that did not show any tumor growth after 5 weeks of their injection with CIITA-
transfected tumor cells were challenged with a s.c. injection of 2x105 parental tumor cells (four 
times the number of the first CIITA-expressing tumor cell injection). 
Each experiment was repeated at least twice using 5-8 mice per group. All animal work has been 
conducted according to relevant national and international guidelines and was approved by the 
University of Insubria Internal Ethical Committee CESA (project 07-2013) and by the Italian 
Ministry of Health. 
 
4. Ex vivo MC38-CIITA tumors analysis  
MC38-CIITA outgrowing tumors were excised from mice and a single cell suspension was 
obtained from each tumor by dissociation with a sterile syringe plunger in a 70 µm cell strainer. 
The level of expression of MHC-I and MHC-II on the surface of the ex vivo tumor cells was 
assessed by immunofluorescence staining and flow cytometry analysis as described above. 
  
5. ELISA analysis 
Spleens were harvested from naïve mice, MC38 tumor-bearing mice and MC38-CIITA 
vaccinated mice originating from the same experiment. Single cell suspension was obtained from 
each spleen by dissociation with a sterile syringe plunger in a 70 µm cell strainer, then, after 
centrifugation for 15 minutes at 1500 rpm and discarding the supernatant, the cells were treated 
with Ammonium Chloride Potassium or ACK lysing buffer for 3 minutes on ice in order to lyse 
the erythrocytes. The obtained splenocytes from the different spleens were plated in a 48 wells 
plate in triplicate, at a concentration of 4x106 cells /well. The supernatant was assessed for of the 
secretion of IFN-γ after 4 days of culture using Mouse IFN-γ Ready-SET-Go ELISA kit 
(Affymetrix eBiosceience, Catalog number: 88-7314) following the manufacturer’ protocol. 
  
6. Adoptive cell transfer 
Spleens from challenged mice that did not show parental tumor growth after 4 weeks from 
injection were harvested and processed as mentioned above. A single cell suspension was 
obtained and used to purify CD4+, CD8+ T cells (Mouse T Cell Isolation Kit, Miltenyi Biotec 
GmbH, cat. number 130-095-248/130-090-859 respectively), or CD19+ B cells using Easy Sep 
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Mouse B Cell Enrichment Kit (STEMCELL TechnologiesTM, catalog number: 19754). The 
purity of the purified cells was confirmed by flow cytometry using 145-2C11 anti-CD3e (Becton 
Dickinson, Catalog number: 553066), RM4-5 anti-CD4 (Becton Dickinson, Catalog number: 
550954), 53-6.7 anti-CD8a (Biolegend®, Catalog number: 100711) and 6D5 anti-CD19 
(Biolegend®, Catalog number: 115511) antibodies. 
Normal splenocytes were obtained from naïve C57BL/6 female mice of the same age. Naïve 
female mice, 7-9 weeks old, were s.c. co-injected with 2x105 parental MC38 tumor cells, in a 
100 µl volume of RPMI without FCS, along with either immune total splenocytes, CD4+ T cells, 
CD8+ T cells, CD19+ B cells, or total naïve splenocytes as a control, in a tumor cells:immune 
cells ratio of 1:50, 1:15, 1:10, 1:25 and 1:50 respectively. The experiment was repeated at least 
twice using 5-8 mice per group. The mice under experimentation were followed for 4 to 5 weeks 
and the data were recorded as described before. 
 
7. Dendritic cells depletion in CD11c.DTR transgenic C57BL/6 mice 
CD11c.DTR heterozygous C57BL/6 mice (kindly provided by Dr. N. Garbi, University of Bonn, 
Germany) express Diphtheria Toxin Receptor (DTR) under the control of the CD11c gene 
promoter that is highly expressed in DCs. Depletion of DCs (CD11c+/MHC-II+) can be obtained 
by injecting these mice with Diphtheria Toxin (DT), whose cytotoxicity is strictly dependent on 
receptor-mediated endocytosis [15]. CD11c.DTR heterozygous transgenic male mice were bred 
with wild type (WT) C57BL/6 females purchased from Charles River Laboratories. Genotyping 
was performed on the offsprings in order to select the transgenic progeny. The DNA was 
extracted from tail-cuts and PCR was done for the β2 microglobulin (βm) as a reference gene 
and for the Ovalbumin (OVA) as a reporter gene located downstream the DTR gene under the 
control of the same CD11c gene promoter. The following primers were used in PCR: 
 
OVA1 5’-AACCTGTGCAGATGATGTACCA-3’ 
OVA2 5’-GCGATGTGCTTGATACAGAAGA-3’ 
 
βm 1 5’-CACCGGAGAATGGGAAGCCGAA-3’  
βm 2 5’-TCCACACAGATGGAGCGTCCAG-3’ 
 
Primers were obtained from Tib Molbiol Srl, Genova, Italy. Following the protocol established 
by Hochweller et al., [15] the selected transgenic female mice (7-9 weeks old) were daily injected 
intraperitoneally (i.p.) with DT (SIGMA-ALDRICH, Catalog number: D0564) for 11 days 
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starting 48 hours prior to tumor injection. Each mouse was injected with 8 ng/gbw of DT in a 
100 µl volume of RPMI without FCS. DCs depletion was confirmed by immunofluorescence and 
flow cytometry analysis of CD11c+ cells, using the HL3 anti-CD11c antibody (Becton 
Dickinson, Catalog number: 561044), and the M5/114.15.2 anti-IA antibody on splenocytes 
isolated from transgenic mice sacrificed 72 hours after their first DT injection and compared to 
splenocytes of wild type mice. 
5x104 MC38-CIITA tumor cells were s.c. injected in DT treated and untreated CD11c.DTR 
C57BL/6 female mice. Each group consisted of at least 5 mice. The experiment was repeated 
three times. The mice under experimentation were followed for 4 weeks and the data were 
recorded as described before. 
 
8. Macrophages depletion with liposomal Clodronate 
250 µl of 5 mg/ml Liposomal Clodronate (LClo) (http://www.clodronateliposomes.org), a potent 
anti-macrophage agent that upon phagocytosis induces an irreversible damage of the cell which 
then dies by apoptosis [34], were injected i.p. every 3 days for 2 weeks starting 4 days before 
tumors injections. Macrophages depletion was confirmed by flow cytometry analysis of 
peritoneal and spleen cells stained with BM8 anti-F4/80 antibody (Biolegend®, Catalog 
number:123107) and the M5/114.15.2 anti-IA antibody, on the following day of the second LClo 
injection. 
Equal number (5x104) of MC38-CIITA tumor cells were s.c. injected in LClo-treated and 
untreated C57BL/6 female mice. Each group contains at least 5 mice. The experiment was 
performed two times. The mice under experimentation were followed for 4 weeks and the data 
were recorded as described before. 
 
9. Statistical analysis 
The statistical analyses were carried out using GraphPad Prism 6 and Student t-test was run to 
determine the significance. The results were considered significant if p values were < 0.01. 
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Part III. 
Chapter 2: Results 
 
1. CIITA-transfected MHC-II positive MC38 clone generation 
As shown in previously published work using cell lines from different histotypes of the H-2d 
haplotype [12], the transfection of CIITA triggered the expression of MHC-II (or I-A) also in the 
MC38 colon carcinoma cell line of H-2b haplotype. The cells were stably transfected and different 
steps of sorting by magnetic beads and limited dilution cloning were made in order to obtain a 
single stable CIITA-transfected MHC-II positive clone. The MHC-II expression during these 
steps was assessed by immunofluorescence and the selected clone was further used in the 
experiments (Fig. 1). 
	
Fig. 1 MHC-II positive MC38-CIITA clone generation. The expression of MHC-II (I-A) on the surface of MC38 
tumor cells was assessed at different steps after their stable transfection with CIITA. Immunofluorescence followed 
by flow cytometry analyses were done using the specific antibodies. From the left to the right panel we can see, first 
the MC38 parental cells that were negative for MHC-II; second the CIITA-transfected bulk of cells after being sorted 
by magnetic beads and being all positive for MHC-II; third the selected single clone after limited dilution cloning 
of the previous bulk and presenting a stable high level of expression of MHC-II. Results are expressed as number of 
cells (ordinate) versus the mean of fluorescence intensity (m.f.i.) in arbitrary units (abscissa). In each histogram, 
negative controls, obtained by staining the cells with an isotype-matched antibody, are depicted as dashed lines. 
Moreover, MC38-CIITA stable clones underwent different studies in order to study the effect of 
the expression of CIITA on the cells. 
Firstly, the stable clones were assessed for their expression of costimulatory molecules such as 
CD80 and CD86 that are involved in the MHC-II restricted antigen presentation. Results 
indicated that MC38-CIITA tumor cells were negative for these two markers, just like the 
parental tumor cells (Fig. 2). 
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Fig. 2 Lack of the expression of CD80 and CD86 costimulatory molecules on both parental and CIITA 
transfected tumor cells. The expression of CD80 and CD86 co-stimulatory molecules (first two rows of vertical 
panels) was assessed on parental MC38 and MC38-CIITA tumor cells by immunofluorescence and flow cytometry 
and with the corresponding specific antibodies. The cells were also assessed for the expression of CD11b and MHC-
II (I-A) markers (third and fourth row of vertical panels, respectively). As positive control for the expression of the 
4 markers, a population of activated peritoneal macrophages from C57BL/6 mice was analyzed. Results are 
expressed as number of cells (ordinate) versus the mean of fluorescence intensity (m.f.i.) in arbitrary units (abscissa). 
In each histogram, negative controls, obtained by staining the cells with an isotype-matched antibody, are depicted 
as dashed lines. 
 
Secondly, a proliferation test was performed on the stable transfected MC38-CIITA clone in 
comparison with the parental MC38 in order to evaluate if the CIITA expression affected the 
proliferation rate of the cells in vitro. No significant difference was detected between the 
proliferation rate of the CIITA-transfected and parental cells during three days of culture in vitro 
(Fig. 3). 
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Fig. 3 No effect for CIITA gene expression on the proliferation rate of MC38-CIITA. The average number of 
viable cells was calculated from the three plated wells for each cell type at different time points and presented 
(ordinate) over time in hours (abscissa). 
	
	
2. CIITA-driven MHC-II+ tumor cells are rejected or strongly retarded in 
their growth 
Following the preliminary in vitro studies we moved to the in vivo ones in order to investigate 
the effect of CIITA expression on the anti-tumor immune response of the mice. MC38-CIITA 
and MC38 parental tumor cells were injected into naïve syngeneic C57BL/6 mice and tumor 
growth was monitored over time. MC38-CIITA tumor cells were either completely rejected or 
showed a significant retardation in their growth in vivo in comparison with their parental 
untransfected counterpart. In fact, after 5 weeks, 50% of the mice injected with MC38-CIITA 
did not develop any tumor (Fig. 4; a), and those that developed tumors displayed a growth 
kinetics 4 to 5 fold reduced as compared to the parental tumor growth that occurred in 80% of 
the injected mice (Fig. 4; b). 
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Fig. 4 MC38-CIITA tumor cells are rejected or drastically retarded in their growth in vivo. Equal number 
(5x104) of either parental MC38 or MC38-CIITA tumor cells were injected subcutaneously (s.c.) in 7-9 weeks old 
C57BL/6 female mice (at least 5 mice per group). Tumors growth along with the overall health condition of the mice 
were checked at least twice per week. (a) The percentage of tumor-free mice in both groups (ordinate) is presented 
as a function of time in days (abscissa). (b) The average size of tumors growing in each group is presented in mm2 
(ordinate) as a function of time in days (abscissa). Data represent means from more than two different experiments. 
Open symbols refer to parental tumor cells; full symbols refer to CIITA-transfected tumor cells. Differences between 
both groups in the graph of average tumor size kinetics were significant (p value < 0.01) at all-time points. 
 
3. MC38-CIITA tumor cells trigger a long lasting adaptive immune response 
To investigate whether the rejection and/or the growth retardation of MC38-CIITA tumors was 
due to an adaptive immune response and in order to further understand this response, we first 
challenged with parental MC38 cells the protected mice that did not show any tumor growth for 
five weeks after being injected with MC38-CIITA. The challenge was done by injecting four 
times the number of cells that was used to vaccinate the mice with MC38-CIITA. Interestingly, 
100% of the challenged mice were protected and did not show any tumor growth compared to 
naïve mice that all display tumor growth after 2 weeks (Fig. 5; a, b). These results clearly 
demonstrate the acquisition of a long-lasting specific immune response not only against the 
immunizing CIITA-positive, MHC-II-positive tumor but also against the MHC-II-negative 
parental tumor. 
 
a b 
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4. Loss of MHC-I and MHC-II by the MC38-CIITA growing tumors 
In order to understand why some mice developed tumors after injection of CIITA-transfected 
MC38 cells, freshly excised tumors from the MC38-CIITA tumor-bearing mice were assessed 
for their expression of MHC-I and MHC-II cell surface molecules by immunofluorescence and 
FACS analysis. Interestingly, these tumors presented with a loss of MHC-I expression and more 
importantly with a strongly reduced MHC-II expression as well, indicating that they underwent 
immunoediting in vivo to escape recognition by the immune system (Fig. 6). 
b a 
Fig. 5 Vaccination with MC38-CIITA induces long lasting immunity against MC38 parental tumor. Mice 
resistant to MC38-CIITA (MC38-CIITA protected) tumor growth or naïve control mice were challenged with 
2x105 parental tumor cells. (a) The percentage of tumor-free mice is presented (ordinate) as a function of time in 
days after injection (abscissa). (b) The average size in mm2 of the tumors growing in each group is presented 
(ordinate) as a function of time in days after injection (abscissa). Differences between both groups in the graphs 
of average tumor size kinetics were highly significant (p value < 0.001) at all-time points 
37 
	
	
Fig. 6 Loss of MHC-I and low level of MHC-II expression on the ex vivo MC38-CIITA tumors. The expression 
of MHC-I and MHC-II was assessed by flow cytometry on the surface of MC38-CIITA ex vivo tumor cells at the 
day of the excision from the tumor bearing mice. The level of expression of MHC-I and MHC-II on the tumor cells 
at the day of the injection (First horizontal row) and on the excised tumors number 83 and 81 respectively after 4 
weeks of the injection (Second and third horizontal row). Results are expressed as number of cells (ordinate) versus 
the mean of fluorescence intensity (m.f.i.) in arbitrary units (abscissa). In each histogram, negative controls, obtained 
by staining the cells with an isotype-matched antibody, are depicted as dashed lines. 
 
5. High IFN-γ secretion by splenocytes of immune mice 
Beside the excised tumors, spleens were also harvested and IFN-γ secretion from splenocytes 
excised from naïve mice, MC38 tumor bearing mice or MC38-CIITA protected mice was 
assessed by ELISA. Results showed a high secretion of IFN-γ by the splenocytes of immune 
mice, about 1500 pg/ml, in comparison with a much lower level of IFN-γ secretion by naïve or 
tumor bearing mice splenocytes, around 500 pg/ml (Fig. 7). The high level of IFN-γ secretion 
reflect a strong activation of the immune system of the MC38-CIITA protected mice and favors 
a cellular immune response mediated by CD4+ TH1 subset. 
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Fig. 7 Immune activated splenocytes from MC38-CIITA vaccinated mice secrete high level of IFN-γ. ELISA 
analyses were performed on the supernatant of 4x106 splenocytes from naïve, immune or tumor bearing mice put in 
culture for 4 days. Each culture was made in triplicates and the ELISA wells were made in duplicates. 
	
6. The long lasting immune response triggered by MC38-CIITA is 
orchestrated by CD4+ T cells 
 The previously presented results clearly demonstrated that the vaccination with CIITA-driven 
MHC-II positive MC38 tumor cells triggers a long lasting adaptive anti-tumor immune response.   
To identify the immune cells responsible of the tumor rejection in vaccinated animals, total 
splenocytes, purified CD4+ T cells, CD8+ T cells or B cells of vaccinated and challenged mice 
were used in adoptive cells transfer (ACT) experiments.  
As shown in Fig. 8, total splenocytes from MC38-CIITA protected and challenged mice (immune 
mice) confer protection to 100% of the injected mice against the tumor growth. Purified CD4+ 
T cells from immune mice were also efficacious in preventing tumor growth of MC38 parental 
tumor since 80% of the animals were protected (Fig. 8; a) and the remaining 20% presented a 
retarded growth (Fig. 8; b). Conversely, neither protection nor retardation of tumor growth was 
observed by injection of spleen cells from naïve animals or of purified B cells from vaccinated 
animals. Surprisingly, purified CD8+ T cells were only partially effective in preventing tumor 
growth, as only 20% of the animals were protected and the remaining 80% did not displayed 
potent growth retardation, suggesting that the primed CD8+ T cells are not sufficient to trigger a 
potent immune response against the parental tumors (Fig. 8; a and b). These findings are in 
contrast to that observed in the Balb/c system, in which both CD4+ and CD8+ T cells act equally 
well as effector immune cells against the tumors [12].	 
39 
	
	
	
7. CIITA driven MHC-II positive MC38 tumor cells act as surrogate APCs for 
priming and activating CD4+ TH cells 
 The results presented in Fig. 8 clearly show that CD4+ TH cells were the responsible lymphocyte 
subpopulation capable of transferring anti-tumor protection to naïve mice. In order to assess the 
direct role of the CIITA-driven MHC-II expressing tumor cells as surrogate antigen presenting 
cells in vivo, we took advantage of a recently described transgenic mouse model, the CD11c.DTR 
C57BL/6 mice expressing the DTR gene along with the OVA gene downstream the promoter of 
CD11c gene that is highly expressed in DCs. In this system, DCs, believed to be the crucial cells 
for T cell priming, can be transiently depleted in vivo by injecting the mice with DT, offering the 
possibility to study an anti-tumor immune response in absence of this crucial APCs population 
[15].  
CD11c.DTR mice were first selected after extracting DNA from their tail cuts and performing 
PCR in order to detect the presence of the OVA (Fig. 9). 
 
a b 
Fig. 8 CD4+ TH cells are the key cells responsible for the anti-tumor immunity induced after MC38-CIITA 
vaccination. Spleens from protected mice were isolated and processed to purify CD4+, CD8+ T cells, and B cells. 
Naïve mice were co-injected s.c. with 2x105 MC38 parental cells together with either immune total splenocytes, 
purified CD4+ T cells, CD8+ T cells, CD19+ B cells, or with total naïve splenocytes, as a control. (a) The percentage 
of tumor-free mice in each group is presented in (ordinate) as a function of time in days after co-injection (abscissa). 
(b) The average size in mm2 of tumors growing is presented (ordinate) as a function of time in days after co-injection 
(abscissa). No statistical significance was observed in the growth of tumors after adoptive cell transfer of naïve 
splenocytes and immune CD19+ B cells in MC38 group. Statistical significance was observed between naïve 
splenocytes or CD19+ B cells and immune splenocytes (p value < 0.01) and CD4+ T cells (p value < 0.01) at all time 
points, and with CD8+ T cells (p value < 0.01) after 21 days. 
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Fig. 9 CD11c.DTR mice genotyping. PCR samples were loaded on 2% agarose gel with Ethidium Bromide staining, 
and DNA was visualized under ultra violet exposure. Mice number 3, 4, 5, 6 and 8 are transgenic since they express 
the reporter OVA gene. βm is the reference or housekeeping gene that is present in all the samples. 
 
 The detected CD11c.DTR mice, were injected with DT following the protocol described in 
Materials and Methods. The kinetics of the MC38 and MC38-CIITA tumor take and tumor 
growth was followed over time. DCs depletion in tumor-injected mice was assessed by 
immunofluorescence followed by flow cytometry of spleen cells co-stained with anti-CD11c and 
anti-MHC (I-A) antibodies, since the most prominent DCs population displaying APCs activity 
expresses both these markers. Indeed, DT treatment of CD11c.DTR transgenic mice was able to 
virtually deplete the entire DCs population from the spleen (Fig. 10; a).  
 After DCs depletion 35% of mice injected with MC38-CIITA tumor cells fully rejected the tumor 
after 4 weeks from tumor cell injection. This proportion was similar to the one obtained in mice 
not undergoing DCs depletion (40%, Fig. 10; b, left panel). Moreover, the MC38-CIITA tumors 
that developed in DCs-depleted mice displayed a significant retardation in their growth and a 
strong reduction in their volume. This growth kinetics was indeed superimposable to that 
obtained in DT-untreated mice without DCs depletion (Fig. 10; b, right panel). 
These results show that CIITA-tumor cells can still induce a potent immune response in vivo 
despite the absence of DCs the most prominent antigen presenting cells and the ones considered 
to be crucial for the initial priming of naïve antigen-specific CD4+ TH cells.  
1    2   3    4   5    6    7    8   9  10
100bp
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βm
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 In order to exclude the possibility that in absence of DCs other professional APCs, such as 
macrophages, could provide specific tumor antigen priming for naïve CD4+ T cells, CD11c.DTR 
transgenic mice were treated with liposomal clodronate (LClo), a chemical compound that is a 
potent anti-macrophage agent both in vivo and in vitro. In fact, after being phagocytosed by 
macrophages the clodronate is accumulated intracellularly and after exceeding a threshold 
concentration, the cells are irreversibly damaged and die by apoptosis 
(http://www.clodronateliposomes.org).  
a 
b 
Fig. 10 MC38-CIITA tumors cells are the only APCs (DCs Depletion). (a) CD11c.DTR transgenic mice were 
treated with diphtheria toxin (DT) as described before. DCs depletion was checked after 3 days from the first DT 
injection by immunofluorescence and FACS analysis on spleen cells co-stained with anti-CD11c and anti- I-A 
directly labelled monoclonal antibodies and compared with the one in untreated mice. (b) Equal number (5x104) of 
MC38-CIITA tumor cells were injected in either untreated (MC38-CIITA) or DT-treated (MC38-CIITA + DT) 
CD11c.DTR transgenic mice. A group of untreated mice were also injected with the same number of parental MC38 
cells, as control (MC38). Tumor take, measured as percentage of mice with tumors (ordinate, left panel) and kinetics 
of tumor growth (ordinate, right panel) were followed over time (days in abscissa). 
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Following the protocol described in Materials and Methods, CD11c.DTR female mice were 
injected with LClo. To control that the treatment was effective, spleens cells as well as peritoneal 
macrophages from treated mice were preliminary analyzed for the expression of the F4/80 
macrophage marker as well as for the expression of MHC-II molecules present on macrophages 
also. Results presented in Figure 11 clearly show that a strong depletion of both splenic 
macrophages (panel a) and peritoneal macrophages (panel b) was obtained after LClo treatment.  
LClo-treated mice were then injected with MC38-CIITA tumor cells and in vivo tumor growth 
was evaluated over time. 40% of animals were able to reject MC38-CIITA tumor cells after 4 
weeks, exactly the same proportion rejecting the tumor cells in control animals not treated with 
LClo (Fig. 11; c, left panel). Again, even in the case of LClo-treated animals, the kinetics of 
MC38-CIITA tumor growth in 60% of animals that did not reject the tumor was strongly retarded 
a b 
c 
Fig. 11 MC38-CIITA tumors cells are the only APCs (Macrophages Depletion). (a) Splenocytes and (b) 
peritoneal macrophages were taken from mice treated with LClo as described previously and analysed by 
immunofluorescence co-staining and flow cytometry, for the expression of I-A, and F4/80 using their corresponding 
directly labelled monoclonal antibodies and compared to untreated mice as a control. (c) Equal number (5x104) of 
MC38-CIITA tumor cells were injected in either untreated (MC38-CIITA) or LClo-treated (MC38-CIITA + LClo) 
CD11c.DTR transgenic mice. A group of untreated mice was also injected with the same number of parental MC38 
cells, as control (MC38). Tumor take, measured as percentage of mice with tumors (ordinate, left panel) and kinetics 
of tumor growth (ordinate, right panel) were followed over time (days in abscissa). 
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as compared to the one of parental tumors and closely followed the kinetics of MC38-CIITA 
tumors growing in animals that did not undergo LClo treatment (Fig. 11; c, right panel).  
Taken together, these results indicate that CIITA-tumor cells can trigger a protective anti-tumor 
immune response not only in absence of dendritic cells but also in absence of macrophages. 
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Part III. 
Chapter 3: Discussion and Conclusion 
 
Our previous studies have demonstrated that CIITA-driven MHC-II gene expression in tumor 
cells of the H-2d genetic background can indeed render these cells potent stimulators of a 
protective and long lasting adaptive anti-tumor immune response capable to protect the syngeneic 
vaccinated animals against a challenge with MHC-II negative parental tumors and to transfer this 
protection to naïve recipient by MHC-II-restricted  CD4+ TH cells [10], [11], [12], [35]. In the 
present study we extended this observation to tumor cells of the H-2b genetic background, which 
at variance with H-2d genotype can express only one of the two MHC-II molecules, the I-A but 
not the I-E molecule. MC38 colon carcinoma tumor cell line, that is MHC-II-negative and highly 
tumorigenic in vivo, became strongly immunogenic after de novo expression of MHC-II 
molecules mediated by CIITA transfection. Although we could not reach the percentage of full 
rejection of certain Balb/C tumor cell lines such as the TS/A mammary carcinoma or the WEHI 
164 fibrosarcoma [12], [35], up to 50% of animals were able to reject MC38-CIITA tumor cells. 
Importantly, however, the remaining animals that did not reject the tumor developed an immune 
response capable to significantly reduce tumor growth, indicating that all animals were indeed 
responding against the tumor. The reason of absence of full rejection in the second group of mice 
is most likely related to the possible in vivo modulation of MHC-II and MHC-I expression in the 
injected tumor cells, as we previously observed [10], [35] and confirmed here. Importantly, all 
rejecting animals were resistant to challenge with parental MHC-II negative tumors and their 
CD4+ TH cells could transfer protection to naïve H-2b C57BL/6 mice. These results, definitively 
establish the general validity of our approach and demonstrate that tumor cells of distinct genetic 
background and distinct histotypes origin can become immunogenic when expressing CIITA-
driven MHC class II molecules. Importantly, the present results indicate that a single MHC-II 
restricting element, the I-A molecule, could bind sufficient tumor-associated antigens to mediate 
CD4+ TH cell recognition and triggering of adaptive anti-tumor responses in vivo. Although our 
system is presently confined to an animal approach in which no complete genetic analysis of the 
tumor mutation rate is available, it is important to stress that the approach works also for tumors 
like sarcomas with low genetic mutation rate. Thus, we think that this is an advantage over the 
present human therapies based on antibodies to checkpoint inhibitors in which best results are 
obtained with tumors of high genetic mutation rate [36], [37]. 
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Although we have previously clearly demonstrated that the MHC-II molecules of tumor cell 
origin were necessary to mediate the triggering process of the key lymphocytes initiating and 
maintaining the anti-tumor state, that is the CD4+ TH cells, we could not firmly establish whether 
the CIITA-tumor cells were indeed themselves the prominent APCs capable to perform in vivo 
priming of naïve TH cells. Indeed, the possibility existed that, upon injection, MHC-II-TAA 
complexes derived from dying cells or from cell debris could be captured by DCs and used by 
these professional APCs to trigger and prime naïve CD4+ TH cells. This crucial point was 
addressed in the present study by the use of the CD11c.DTR transgenic mice, constructed in a 
C57BL/6 H-2b background, expressing the diphtheria toxin receptor under the control of the 
CD11c promoter, mainly expressed in DCs. In these mice, DCs could be conditionally deleted 
by treatment with diphtheria toxin [15]. Our results clearly demonstrate that MC38-CIITA 
tumors cells can still be rejected or strongly delayed in their growth in DT-treated CD11c.DTR 
transgenic mice in a way very similar to that obtained in untreated counterpart or in non-
transgenic C57BL/6 mice. Moreover, although it has been reported that DT treatment of 
CD11c.DTR transgenic mice may also partially ablate macrophages [38], [39], the other 
important professional APCs in vivo, we treated CD11c.DTR transgenic mice with Liposomal 
Clodronate, a compound that upon selective phagocytosis  by macrophages kills the cells by 
apoptosis [40], and in the spleen ablates particularly the marginal zone macrophages and 
metallophilic macrophages considered the predominant APCs [41]. 
Again, upon injection, CIITA-tumor cells could be rejected or strongly retarded in their growth 
with superimposable behavior as the one observed in liposomal-untreated mice. Thus, CIITA-
driven MHC-II positive tumor cells can perform not only antigen processing and presenting 
function in vitro [10], [42] but they can also serve as surrogate APCs in vivo to prime naïve CD4+ 
TH cells and induce potent adaptive immune response against the tumor.  
Our results challenge the widely accepted view that antigen priming of naïve tumor-specific 
CD4+ TH cells in vivo can be optimally performed only by professional APCs and particularly 
by DCs [43]. This view has been supported by the notion that optimal stimulation of naïve TH 
cells requires two signals, the first provided by the antigen-specific T cell receptor recognizing 
MHC-II-antigenic peptide complex, and the second provided by the CD28 molecule interacting 
with co-stimulatory molecules such as the B7.1 (CD80) and B7.2 (CD86) optimally expressed 
on DCs [44]. Even if tumor cell may express in certain cases MHC-II molecules, they do not 
express in general costimulatory molecules such as CD80 and CD86 and thus they cannot provide 
the second signal. MC38 tumor cells used in this study do not express CD80 and CD86 
costimulatory molecules and this phenotype is not modified by CIITA transfection (Fig. 2). Yet, 
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the absence of costimulatory molecules does not prevent CIITA-driven MHC-II expressing 
tumor to act as potent surrogate APCs in vivo. Thus, either CIITA-tumors do not need accessory 
molecules to perform their APCs function in vivo, or other accessory molecules are involved to 
provide the second signal. Future investigation will be focused on this important issue. 
Another important consideration that stems from our studies relates to the anatomical location 
where CIITA-tumor cells’ APC function takes place. It is widely accepted that priming of 
antigen-specific naïve CD4+ T cells by professional APCs takes place in secondary lymphoid 
organs such as lymph nodes and spleen. There, DCs that have captured and processed the 
antigens in the periphery migrate and present antigenic peptides within the context of MHC-II 
molecules [45]. However, previous studies of our group have shown that, in contrast to parental 
tumors where leukocyte infiltrate is scanty, CIITA-tumors rapidly become infiltrated first by 
CD4+ T cells and subsequently by other cells such as DCs, CD8+ T cells and macrophages [10], 
thus reorienting the tumor microenvironment from a pro-tumor to an anti-tumor 
microenvironment [5]. Moreover, it has been shown that lymphocytes can organize themselves 
in lymphoid tissues different from classical lymph nodes, the so-called tertiary lymphoid organs 
or ectopic lymphoid-like structures, peculiar lymphoid formations found in inflamed and, 
interestingly, in tumoral tissues [46]. They show many  characteristics of lymph nodes associated 
with the generation of an adaptive immune response [47]. Thus it is tempting to speculate that 
tumor cells endowed with CIITA-driven MHC-II expression not only may exert full APCs 
function for priming naïve tumor-specific CD4+ T cells but may also perform this activity within 
the tumor tissue itself where a rudiment of organized lymphoid structure can be generated. 
Finally, considering the high in vivo immunogenicity of CIITA-driven MHC-II expressing 
tumors it is clear that these tumor cells optimally express the relevant MHC-II-TAA complexes 
and key neoantigens for immune stimulation. These cells therefore may be instrumental to purify 
and sequence the key TAA that in conjunction with similarly derived HLA class I-restricted TAA 
peptides, will be the basis for the construction of a multi-peptide, multi-epitope vaccine that can 
target both CD4+TH and CD8+ CTL anti-tumor responses.  
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